Many physicians reported in a survey that a Medicare decision on erythropoiesis stimulating agents has hurt their patients.
A survey of 307 oncologists and hematologists has found that 91% believe that their patients have suffered an adverse event following the implementation of the new Medicare coverage criteria for US Oncology and conducted by KJT Group, found that adverse events have ranged from potentially avoidable transfusions (73%) to patients remaining anemic despite ESA use according to the NCD (65%). The study results demonstrate that the medical community believes the NCD does not represent the prevailing medical evidence or the best interests of patients.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.